Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/eocgCfbwocfFgjaJzTvW

March 21, 2013
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
Safinamide Hits Endpoints in Two Parkinson's Phase III Trials
Newron Pharmaceuticals SpA and its partner, Zambon SpA, remain on track to file for approval for safinamide as add-on therapy in Parkinson's disease in the fourth quarter, following the release of pivotal Phase III data at the annual meeting of the American Academy of Neurology in San Diego this week. Find out the details.

  Health Care & Policy 
  • Biogen reports MS drug trial results at neurology meeting
    A trial found that Biogen Idec's experimental drug peginterferon beta-1a cut the annual rate of relapse by 36% compared with placebo in patients with multiple sclerosis when given every two weeks. The study of the injectable drug, which would be sold as Plegridy is approved, was presented at a meeting of the American Academy of Neurology. Reuters (3/20) LinkedInFacebookTwitterEmail this Story
Selling your business? Here are 7 things you should do now.
If you're considering selling your business, you should be doing everything you can to get the best possible price. In just 7 simple steps you can improve your chances of attracting buyers and getting big bucks for your business. Read the article and learn the 7 steps.

  Company & Financial News 
 
Clinical Trial Data Transparency Forum: Expert insights
Hear industry and academic thought leaders - from Duke Clinical Research Institute, GlaxoSmithKline, Eli Lilly and more - share valuable insight on their clinical trial data transparency and sharing initiatives. This video covers a number of key perspectives and trends.

  Industry Deals 
  • Biolife, Pevion enter manufacturing agreement for cancer vaccine
    Pevion Biotech agreed to manufacture Biolife Science's HER-Vaxx cancer vaccine for use in midstage trials for the treatment of gastric cancer. Pevion will be eligible for royalties on eventual sales of HER-Vaxx, which was developed using Pevion's vaccine technology and Biolife's peptides. Biolife plans to submit the vaccine for FDA approval in the third quarter. Australian Life Scientist (3/19) LinkedInFacebookTwitterEmail this Story
  Food & Agriculture 
  Industrial & Environmental 
  • Plan to cut Pentagon's biofuels budget falters in the Senate
    The Senate rejected an amendment that would have transferred $60 million from the Pentagon's drop-in biofuels budget to its operations and management budget. Sen. Mark Udall, D-Colo., hailed his colleagues' decision, saying military dependence on "foreign fossil fuels and decades-old power systems" is a liability. The Hill/E2 Wire blog (3/20) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • Are you taking full advantage of your membership?
    BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
A community is like a ship; everyone ought to be prepared to take the helm."
--Henrik Ibsen,
Norwegian playwright


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.® Legal Information